Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
149.80B
Market cap149.80B
Price-Earnings ratio
19.42
Price-Earnings ratio19.42
Dividend yield
6.53%
Dividend yield6.53%
Average volume
36.25M
Average volume36.25M
High today
$26.80
High today$26.80
Low today
$26.29
Low today$26.29
Open price
$26.60
Open price$26.60
Volume
29.32M
Volume29.32M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$21.97
52 Week low$21.97

Stock Snapshot

The current Pfizer(PFE) stock price is $26.39, with a market capitalization of 149.8B. The stock trades at a price-to-earnings (P/E) ratio of 19.42 and offers a dividend yield of 6.5%.

On 2026-05-02, Pfizer(PFE) stock traded between a low of $26.29 and a high of $26.80. Shares are currently priced at $26.39, which is +0.4% above the low and -1.5% below the high.

The Pfizer(PFE)'s current trading volume is 29.32M, compared to an average daily volume of 36.25M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $21.97.

In the last year, Pfizer(PFE) shares hit a 52-week high of $28.75 and a 52-week low of $21.97.

PFE News

Simply Wall St 18h
Pfizer’s ELREXFIO Data Reshapes Multiple Myeloma Outlook And Revenue Story

Pfizer (NYSE:PFE) reported positive Phase 3 results for ELREXFIO (elranatamab) in the MagnetisMM-5 study in adults with relapsed or refractory multiple myeloma....

Pfizer’s ELREXFIO Data Reshapes Multiple Myeloma Outlook And Revenue Story
TipRanks 20h
Arvinas Gains First FDA Approval for Breast Cancer Drug

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

Seeking Alpha 21h
Pfizer, Arvinas breast cancer therapy approved by the FDA

The U.S. Food and Drug Administration on Friday approved vepdegestrant, a breast cancer therapy developed by Pfizer (PFE) and Arvinas (ARVN) under the brand nam...

Pfizer, Arvinas breast cancer therapy approved by the FDA

Analyst ratings

50%

of 30 ratings
Buy
40%
Hold
50%
Sell
10%

More PFE News

Nasdaq 2d
Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?

Key Points High-yield stocks may offer impressive levels of passive income -- but it’s important to understand why the particular stock is high-yield. Dividen...

Should You Forget This High-Yield Pharma Stock and Buy a Growth Name Instead?
Benzinga 3d
Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study

Pfizer Inc. (NYSE:PFE) on Wednesday shared topline results from the late-stage study of its cancer treatment, ELREXFIO (elranatamab). Multiple myeloma is an agg...

Pfizer Says Cancer Therapy Beats Standard Therapy In Late-Stage Blood Cancer Study
TipRanks 3d
Pfizer’s Ritlecitinib Trial Targets Painful Skin Disease, Adding Quiet Upside to PFE’s Pipeline

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions...

TipRanks 3d
Pfizer reports ‘positive’ results from Phase 3 MagnetisMM-5 study

Pfizer (PFE) announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO as monotherapy in adults with relapsed or refractory mul...

Simply Wall St 3d
Is Pfizer Offering Value After Recent Share Price Weakness?

If you are wondering whether Pfizer's current share price reflects its true worth, starting with the recent share performance and valuation checks can help fram...

Is Pfizer Offering Value After Recent Share Price Weakness?
Nasdaq 4d
Should You Buy, Sell, or Hold Pfizer at $27?

Key Points Pfizer's growth rate has tanked in recent years, and investors remain concerned about the future. The company has been loading up on acquisitions t...

Should You Buy, Sell, or Hold Pfizer at $27?
TipRanks 4d
BridgeBio jumps 12% to $83.18 as Pfizer confirms tafamidis settlement

10:18 EDT BridgeBio (BBIO) jumps 12% to $83.18 as Pfizer (PFE) confirms tafamidis settlement Published first on TheFly – the ultimate source for real-time, mar...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.